Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T3CE
|
||||
| Former ID |
DIB016439
|
||||
| Drug Name |
SUPER-LEU-DOX
|
||||
| Synonyms |
CPI-0004; CPI-0004Na; CPI-004Na; DTS-201; TAP-doxorubicin; TSP-doxorubicin; Phthacene-5,12-dione sodium salt; N-[N-(3-Carboxypropionyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucyl]daunorubicin sodium salt; (8S,10S)-10-[3-[N-(3-Carboxy-1-oxopropyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucylamido]-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy]-8-(hydroxyacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrona
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Discontinued in Phase 2 | [1] | ||
| Company |
Diatos SA
|
||||
| CAS Number |
CAS 274912-87-7
|
||||
| Target and Pathway | |||||
| Target(s) | DNA topoisomerase II | Target Info | Modulator | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009260) | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.